Relmada Therapeutics (RLMD): יחס מחיר לרווח לקצב צמיחה

Relmada Therapeutics (RLMD) develops innovative depression therapies through NMDA receptor modulation using the drug REL-1017. The PEG ratio history demonstrates valuation dynamics, where the 0.00 indicator determines the metric's magnitude. The operating model is based on the full outsourcing of production and clinical trials. However, the business relies on speculative esomethadone patents, and success depends on the results of future trials.

Fundamental risks for Relmada Therapeutics (RLMD) require a comparison of the share price with earnings dynamics. For a biotech startup awaiting the commercialization of the drug REL-1017, assessing expansion rates is critical. The current PEG value on the GURU.Markets platform reflects the ratio of the P/E coefficient to the annual growth of net income. A value below one signals that the asset is undervalued relative to its potential. Analysis of the chart allows for a determination of whether the market is adequately pricing management efficiency.